Maravai Lifesciences Holdings (MRVI) AI Stock Analysis

• Market Cap: $943.56M
• Dividend Yield: N/A
• Average Volume (3M): 1.48M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.64
• Revenue Growth: -30.56%
• EPS Growth: 48.79%
• Country: US
• Employees: 570
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 145,022,750
• 10 Day Avg. Volume: 1,141,532
• 30 Day Avg. Volume: 1,479,966
• PEG Ratio: -0.31
• Price to Book (P/B): 2.31
• Price to Sales (P/S): 2.90
• P/FCF Ratio: -33.87
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: 3.78
• Enterprise Value/Gross Profit: 18.10
• Enterprise Value/Ebitda: -5.76
• 1Y Price Target: $4.00
• Price Target Upside: 23.08% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.31
• Revenue Forecast (FY): $184.89M

• Rating: 49 Neutral
• Price Target: $3.50 ▲(7.69% Upside)

Maravai Lifesciences Holdings is currently facing significant financial challenges, with declining revenue and profitability being the most critical factors. Despite positive technical indicators suggesting short-term bullish momentum, the negative valuation metrics and absence of dividends weigh heavily on the stock's attractiveness. The company's strategic initiatives and cost-cutting measures offer some hope for future improvement, but the financial outlook remains pressured.

Positive Factors

Cost Structure Realignment

The significant cost reduction initiative is expected to improve profitability and operational efficiency, enhancing long-term financial stability.

Innovation and Product Launches

New product innovations like ModTail technology can drive future growth and strengthen competitive positioning in the biotech market.

CEO Share Purchase

The CEO's significant share purchase demonstrates confidence in the company's strategic direction and potential for recovery.

Negative Factors

Revenue Decline

The substantial revenue decline indicates challenges in maintaining market share and could impact long-term growth prospects.

Negative Adjusted EBITDA

Negative EBITDA reflects operational inefficiencies and financial strain, which could hinder the company's ability to invest in growth.

Cash Flow Challenges

Negative cash flow trends limit the company's ability to fund operations and strategic initiatives, posing a risk to financial health.

Maravai Lifesciences Holdings Business Overview & Revenue Model

Company Description

Maravai Lifesciences Holdings (MRVI) is a leading provider of life sciences tools and services, focused on enabling the development of new therapies and the advancement of scientific research. The company operates primarily in three sectors: nucleic acid production, protein detection, and cell line development. Its core products include custom nucleic acids, detection reagents, and cell line development services, which are critical for applications in genomics, diagnostics, and biopharmaceutical manufacturing.

How the Company Makes Money

Maravai Lifesciences generates revenue through multiple streams, primarily by providing high-quality nucleic acid products and services to biotechnology and pharmaceutical companies, academic institutions, and contract research organizations. Key revenue streams include sales of custom oligonucleotides, RNA production, and reagents for molecular biology applications. The company also benefits from partnerships with major players in the biopharmaceutical industry, enhancing its market position and driving sales growth. Furthermore, the increasing demand for mRNA-based therapeutics and vaccines, particularly highlighted during the COVID-19 pandemic, has contributed significantly to Maravai's earnings, as its products are pivotal in the development and manufacturing of these innovative therapies.

Maravai Lifesciences Holdings Financial Statement Overview

Summary

Maravai Lifesciences Holdings is facing significant financial challenges, with declining revenue, profitability, and cash flow. The company's operational inefficiencies and cost management issues are evident in the negative margins and cash flow figures. While the debt-to-equity ratio has improved, the negative return on equity and cash flow issues pose risks to financial stability. The company needs to address these challenges to improve its financial health and performance.

Income Statement

Maravai Lifesciences Holdings has seen a significant decline in revenue and profitability. The TTM data shows a negative revenue growth rate of -10.92%, and the net profit margin is deeply negative at -63.05%. The gross profit margin has also decreased significantly compared to previous years, indicating challenges in maintaining cost efficiency. The EBIT and EBITDA margins are negative, reflecting operational inefficiencies and potential cost management issues.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio of 0.15 in the TTM period, which is an improvement from previous years. However, the return on equity is negative at -42.64%, indicating that the company is not generating sufficient returns on shareholders' equity. The equity ratio is relatively stable, but the overall financial health is impacted by declining profitability.

Cash Flow

The cash flow statement reveals a concerning trend with negative operating and free cash flows in the TTM period. The free cash flow growth rate is -52.53%, and the operating cash flow to net income ratio is negative, suggesting cash flow challenges. The free cash flow to net income ratio is positive, indicating some ability to cover net losses, but overall cash flow management appears strained.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	192.28M	259.19M	288.94M	883.00M	799.24M	284.10M
Gross Profit	40.11M	108.31M	140.20M	714.04M	658.68M	204.45M
EBITDA	-126.10M	-156.92M	712.41M	609.99M	585.78M	138.27M
Net Income	-121.24M	-144.85M	-119.03M	220.21M	182.04M	76.89M
Balance Sheet
Total Assets	849.19M	1.01B	1.49B	2.28B	1.92B	1.27B
Cash, Cash Equivalents and Short-Term Investments	243.57M	322.40M	574.96M	632.14M	551.27M	236.18M
Total Debt	35.85M	376.69M	610.97M	585.26M	575.22M	590.78M
Total Liabilities	417.33M	431.04M	697.57M	1.38B	1.37B	1.12B
Stockholders Equity	245.44M	325.29M	416.75M	545.22M	315.50M	88.51M
Cash Flow
Free Cash Flow	-66.33M	-22.19M	60.67M	518.89M	353.72M	126.78M
Operating Cash Flow	-49.44M	7.46M	126.22M	535.98M	368.57M	152.19M
Investing Cash Flow	-34.22M	-24.32M	-122.31M	-267.61M	105.66M	6.07M
Financing Cash Flow	-250.87M	-235.71M	-61.09M	-187.50M	-159.05M	53.21M

Maravai Lifesciences Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRVI, the sentiment is Positive. The current price of 3.25 is below the 20-day moving average (MA) of 3.58, below the 50-day MA of 3.36, and above the 200-day MA of 2.62, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 58.01 is Neutral, neither overbought nor oversold. The STOCH value of 68.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MRVI.

Maravai Lifesciences Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RLAY	59 Neutral	$1.32B	―	-41.14%	―	-16.50%	33.02%
IMTX	56 Neutral	$1.35B	―	-29.01%	―	-27.61%	-69.49%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MRVI	49 Neutral	$943.56M	―	-41.06%	―	-30.56%	48.79%
KURA	47 Neutral	$928.48M	―	-65.10%	―	―	-5.18%
GHRS	45 Neutral	$923.60M	-20.36	-17.86%	―	―	8.16%
IVA	44 Neutral	$616.04M	-0.99	―	―	-12.52%	-82.84%

Maravai Lifesciences Holdings Corporate Events

Maravai Lifesciences Streamlines Board with Recent Resignations

On October 21, 2025, Maravai LifeSciences Holdings, Inc. announced the voluntary resignation of three board members—Benjamin Daverman, Jessica Hopfield, PhD, and Murali Prahalad, PhD—as part of its strategy to streamline its Board of Directors and cut administrative costs. Consequently, the board’s size was reduced from eleven to eight members, effective October 27, 2025. The resignations were not due to any disagreements with the company’s management or policies. Following these changes, R. Andrew Eckert was appointed chair of the Nominating, Governance and Risk Committee and a member of the Audit Committee, while Gregory T. Lucier joined the Nominating, Governance and Risk Committee. The company also accelerated the vesting of all unvested restricted stock unit awards for the departing directors.